佳禾食品(605300.SH):今年椰子比較受歡迎 燕麥奶是自主研發的產品
格隆匯8月10日丨佳禾食品(605300.SH)近期在接待機構投資者調研時表示,目前我們的植物基系列主要分為兩大類。第一類是以椰子為原料的產品,第二類是我們自主研發的燕麥奶產品。2022年產品燕麥奶產品貢獻的收入達千萬級,植物基系列的收入大部分還是椰子類產品貢獻的。椰子更多的是B端椰漿椰子粉, B端客户更多是做成含椰製品,主要客户是奶茶製品。今年椰子比較受歡迎,燕麥奶是我們自主研發的產品,我們計劃將其打造成主力C端產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.